| 26 | 0 | 33 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨直接抗病毒药物（direct-acting antiviral agents, DAAs）治疗对慢性丙型肝炎（chronic hepatitis C,CHC）患者的病毒学应答率及肝功能的影响。方法 采用回顾性观察方法，纳入2023年10月至2024年6月在河南省传染病医院接受DAAs治疗的223例CHC患者，评估DAAs治疗方案的疗效。结果 CHC患者在接受DAAs治疗后，快速病毒学应答率为87.18%，早期病毒学应答率为98.44%,12周持续病毒学应答（12-week sustained virological response,SVR12）率高达99.10%，其中，单纯CHC患者与合并人类免疫缺陷病毒（human immunodeficiency virus, HIV）感染CHC患者的SVR12率差异无统计学意义（P>0.05）。治疗结束后第12周，丙氨酸氨基转移酶（alanine aminotransferase, ALT）、天门冬氨酸氨基转移酶（aspartate aminotransferase, AST）及甲胎蛋白（alpha fetoprotein, AFP）水平均显著低于基线值（均P<0.05），而单纯CHC与合并HIV感染的CHC患者治疗后的ALT、AST及AFP水平之间差异均无统计学意义（均P>0.05）。结论 DAAs治疗不仅在清除HCV方面具有显著疗效，还能显著改善患者的肝功能，降低肝损伤风险，对合并HIV感染CHC患者具有同样疗效。
Abstract：Objective To explore the effect of direct-acting antiviral drugs(DAAs) treatment on the virological response rate and liver function in patients with chronic hepatitis C(CHC). Methods A retrospective observational study was conducted on 223 CHC patients who received DAAs therapy at Henan Infectious Disease Hospital from October 2023 to June 2024. The efficacy of DAA regimens were evaluated. Results After DAA treatment, the rapid virological response rate of CHC patients was 87.18%, the early virological response rate was 98.44%, and the 12-week sustained virological response rate(SVR12) was 99.10%. There was no statistically significant difference in SVR12 rate between CHC patients and those coinfected with HIV(P>0.05). At 12 weeks post-treatment, Alanine aminotransferase(ALT), Aspartate aminotransferase(AST) and Alpha fetoprotein(AFP) were significantly lower than baseline values(P<0.05), while there were no statistically significant differences in ALT, AST and AFP between patients with simple CHC patients alone and those with CHC co-infected with HIV(P>0.05). Conclusion The DAAs treatment not only has significant efficacy in eliminating HCV virus, but also can significantly improve liver function in patients, reduce the risk of liver injury, and has the same efficacy in CHC patients co-infected with HIV.
[1]钟霞，潘建华，童坚.海南某院孕妇HBV、HCV和梅毒螺旋体检测结果分析[J].传染病信息，2021,34(2):160-161. DOI:10.3969/j.issn.1007-8134.2021.02.015.
[2]Brzdęk M, Zarębska-Michaluk D, Invernizzi F, et al. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C[J]. World J Gastroenterol,2023, 29(6):949-966. DOI:10.3748/wjg.v29.i6.949.
[3]王文鑫，刘红虹，毕京峰，等.慢性HCV感染DAA应答特点和长期预后观察研究[J].传染病信息，2021,34(3):208-212.DOI:10.3969/j.issn.1007-8134.2021.03.003.
[4]中华医学会肝病学分会，中华医学会感染病学分会.丙型肝炎防治指南（2022年版）[J].中华传染病杂志，2023,41(1):29-46. DOI:10.3760/cma.j.cn311365-20230217-00045.
[5]Torre P, Festa M, Sarcina T, et al. Elimination of HCV infection:Recent epidemiological findings, barriers, and strategies for the coming years[J]. Viruses, 2024, 16(11):1792. DOI:10.3390/v16111792.
[6]Martinello M, Solomon SS, Terrault NA, et al. Hepatitis C[J].Lancet, 2023, 402(10407):1085-1096. DOI:10.1016/S0140-6736(23)01320-X.
[7]孙力波，鲁俊锋，张海涛，等.直接抗病毒药物治疗肝移植术后HCV感染复发的有效性和安全性分析[J].传染病信息，2022,35(3):228-231. DOI:10.3969/j.issn.1007-8134.2022.03.008.
[8]Bhattacharjee C, Singh M, Das D, et al. Current therapeutics against HCV[J]. Virusdisease, 2021, 32(2):228-243. DOI:10.1007/s13337-021-00697-0.
[9]Mikolasevic I, Kanizaj TF, Bozic D, et al. Metabolism of direct-acting antiviral agents(DAAs)in hepatitis C therapy:a review of the literature[J]. Current drug metabolism, 2021, 22(2):89-98. DOI:10.2174/1389200221999201214224126.
[10]冯凯，黄平，柯柳，等.达诺瑞韦联合索磷布韦治疗慢性丙型肝炎的真实世界临床研究[J].实用医学杂志，2021,37(18):2418-2422.
[11]尚瑞. DAA药物治疗HCV感染者实现SVR后的长期效果的评价[D].延安：延安大学，2023.
[12]González-Corvillo C, Beneyto I, Sánchez-Fructuoso A, et al. Direct-acting antivirals for the treatment of kidney transplant patients with chronic hepatitis C virus infection in Spain:a long-term prospective observational study[J]. Transplant Direct, 2019, 5(12):e510. DOI:10.1097/TXD.0000000000000954.
[13]李娜娜，张永栋.丙型肝炎病毒基因分型的相关研究进展[J].临床医学进展，2023,13(5):7598-7603. DOI:10.12677/ACM.2023.1351061.
[14]张映媛，木唤，许丹青，等.盐酸可洛派韦联合索磷布韦治疗基因3型HCV感染者的效果及安全性分析[J].临床肝胆病杂志，2025,41(6):1075-1082. DOI:10.12449/JCH250612.
[15]Sarrazin C. Treatment failure with DAA therapy:importance of resistance[J]. J Hepatol, 2021, 74(6):1472-1482. DOI:10.1016/j.jhep.2021.03.004.
[16]Shafran SD. HIV coinfected have similar SVR rates as HCV monoinfected with DAAs:it's time to end segregation and integrate HIV patients into HCV trials[J]. Clin Infect Dis, 2015, 61(7):1127-1134.DOI:10.1093/cid/civ438.
[17]Vo TD, Bui VTT, Lam HT, et al. High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C:a cohort study conducted in Vietnam[J]. Pharmacol Res Perspect, 2024,12(5):e70007. DOI:10.1002/prp2.70007.
[18]陈宏宇，亢倩，罗皓，等.真实世界中不同A LT 、AST水平慢性丙型肝炎患者对直接抗病毒药物治疗的病毒学应答及肝纤维化指标变化情况[J].临床肝胆病杂志，2021,37(2):314-317.DOI:10.3969/j.issn.1001-5256.2021.02.014.
[19]Lin CK, Wang SH, Lee TH. Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk[J]. Sci Rep, 2025, 15(1):32312. DOI:10.1038/s41598-025-14861-9.
[20]Kuwano A, Yada M, Tanaka K, et al. Prediction of hepatocellular carcinoma after direct-acting antiviral therapy using Agile 3+and endof-treatment Alpha-fetoprotein levels in patients with hepatitis C[J].JGH Open, 2025, 9(10):e70296. DOI:10.1002/jgh3.70296.
[21]朱冉旭，付学明.丙型肝炎病毒感染者临床治疗现状分析[J].中国临床研究，2023,36(1):45-49+54. DOI:10.13429/j.cnki.cjcr.2023.01.009.
[22]Nguyen K, Jimenez M, Moghadam N, et al. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals[J]. J Clin Transl Hepatol, 2017, 5(1):43-49. DOI:10.14218/JCTH.2016.00057.
基本信息:
中图分类号:R512.63
引用信息:
[1]李琼,邓萌,张志会,等.直接抗病毒药物治疗慢性丙型肝炎真实世界的疗效观察[J].传染病信息,2026,39(02):113-116.
基金信息:
河南省2024年科技攻关项目（242102310204）; 河南省传染病（艾滋病）临床医学研究中心2024年开放课题（KFKT202413）
2026-04-30
2026-04-30